Top Markets
#1 MowCat MowCat +49.07%
#2 Velvet Velvet +36.37%
#3 Derive Derive +21.24%
#4 Quack AI Quack AI +19.75%
#5 Audiera Audiera +19.69%
#6 MarsCoin MarsCoin +16.65%
#7 Bermuda Shorts Bermuda Shorts +16.51%
#8 aPriori aPriori +15.29%
#9 Biconomy Biconomy +13.82%
#10 Geodnet Geodnet +12.49%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Aeterna Zentaris Inc. Aeterna Zentaris Inc.

Aeterna Zentaris Inc.

AEZS
Rank in Stocks #35469
Aeterna Zentaris Inc. operates as a specialized biopharmaceutical company,... Aeterna Zentaris Inc. operates as a specialized biopharmaceutical company, dedicated to the creation and market introduction of both therapeutic drugs and diagnostic tests. Its flagship product, macimorelin, is an orally administered peptidomimetic ghrelin receptor (GHSR-1a) agonist. This compound functions by binding to the GHSR-1a, thereby stimulating the secretion of growth hormone. Macimorelin is employed for diagnosing growth hormone deficiency in both adult and pediatric patients, and is also under investigation for various oncology indications. The drug is marketed commercially under the brand name Macrilen. The company engages in various licensing agreements, prominently with University Wuerzburg. This collaboration encompasses the research, development, manufacture, and commercialization of a prospective COVID-19 vaccine. It also involves developing, producing, and marketing a treatment for neuromyelitis optica spectrum disorder (NMOSD), establishing human 3D intestinal tissue models for infection biology research, and advancing pre-clinical work towards a potential Parkinson's disease therapy. Additionally, Aeterna Zentaris has formed licensing partnerships with Consilient Health Ltd., Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada. Another key collaboration is with The University of Sheffield in the United Kingdom, dedicated to the research, development, manufacturing, and commercialization of parathyroid hormone fusion polypeptides designed to treat primary hypoparathyroidism. Founded in 1990, Aeterna Zentaris Inc. maintains its corporate headquarters in Summerville, South Carolina.
Share Price
$3.97
Last synced: 2024-09-03
Market Cap
$3.86M
Change (1 day)
-1.00%
Change (1 year)
0.00%
Country
US
Trade Aeterna Zentaris Inc. (AEZS)

Category

Healthcare
Revenue for Aeterna Zentaris Inc. (AEZS)
Revenue in Aug 2026 TTM: 0
According to Aeterna Zentaris Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Aeterna Zentaris Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE